Pulmonx Statistics
Total Valuation
Pulmonx has a market cap or net worth of $66.82 million. The enterprise value is $39.43 million.
Important Dates
The next confirmed earnings date is Wednesday, October 29, 2025, after market close.
| Earnings Date | Oct 29, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Pulmonx has 40.75 million shares outstanding. The number of shares has increased by 3.35% in one year.
| Current Share Class | 40.75M |
| Shares Outstanding | 40.75M |
| Shares Change (YoY) | +3.35% |
| Shares Change (QoQ) | +1.19% |
| Owned by Insiders (%) | 2.66% |
| Owned by Institutions (%) | 83.96% |
| Float | 39.66M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.72 |
| Forward PS | 0.69 |
| PB Ratio | 0.97 |
| P/TBV Ratio | 1.00 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.44 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.35, with a Debt / Equity ratio of 0.82.
| Current Ratio | 5.35 |
| Quick Ratio | 4.48 |
| Debt / Equity | 0.82 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -16.66 |
Financial Efficiency
Return on equity (ROE) is -66.88% and return on invested capital (ROIC) is -24.35%.
| Return on Equity (ROE) | -66.88% |
| Return on Assets (ROA) | -21.57% |
| Return on Invested Capital (ROIC) | -24.35% |
| Return on Capital Employed (ROCE) | -44.25% |
| Revenue Per Employee | $311,165 |
| Profits Per Employee | -$195,670 |
| Employee Count | 291 |
| Asset Turnover | 0.57 |
| Inventory Turnover | 1.47 |
Taxes
In the past 12 months, Pulmonx has paid $542,000 in taxes.
| Income Tax | 542,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -73.25% in the last 52 weeks. The beta is 0.42, so Pulmonx's price volatility has been lower than the market average.
| Beta (5Y) | 0.42 |
| 52-Week Price Change | -73.25% |
| 50-Day Moving Average | 1.67 |
| 200-Day Moving Average | 4.03 |
| Relative Strength Index (RSI) | 48.54 |
| Average Volume (20 Days) | 255,274 |
Short Selling Information
The latest short interest is 1.44 million, so 3.53% of the outstanding shares have been sold short.
| Short Interest | 1.44M |
| Short Previous Month | 1.78M |
| Short % of Shares Out | 3.53% |
| Short % of Float | 3.62% |
| Short Ratio (days to cover) | 3.90 |
Income Statement
In the last 12 months, Pulmonx had revenue of $90.55 million and -$56.94 million in losses. Loss per share was -$1.43.
| Revenue | 90.55M |
| Gross Profit | 66.16M |
| Operating Income | -55.20M |
| Pretax Income | -56.40M |
| Net Income | -56.94M |
| EBITDA | -53.95M |
| EBIT | -55.20M |
| Loss Per Share | -$1.43 |
Full Income Statement Balance Sheet
The company has $84.23 million in cash and $56.83 million in debt, giving a net cash position of $27.40 million or $0.67 per share.
| Cash & Cash Equivalents | 84.23M |
| Total Debt | 56.83M |
| Net Cash | 27.40M |
| Net Cash Per Share | $0.67 |
| Equity (Book Value) | 69.09M |
| Book Value Per Share | 1.70 |
| Working Capital | 97.57M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$31.10 million and capital expenditures -$877,000, giving a free cash flow of -$31.98 million.
| Operating Cash Flow | -31.10M |
| Capital Expenditures | -877,000 |
| Free Cash Flow | -31.98M |
| FCF Per Share | -$0.78 |
Full Cash Flow Statement Margins
Gross margin is 73.07%, with operating and profit margins of -60.96% and -62.88%.
| Gross Margin | 73.07% |
| Operating Margin | -60.96% |
| Pretax Margin | -62.28% |
| Profit Margin | -62.88% |
| EBITDA Margin | -59.58% |
| EBIT Margin | -60.96% |
| FCF Margin | n/a |
Dividends & Yields
Pulmonx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.35% |
| Shareholder Yield | -3.35% |
| Earnings Yield | -85.21% |
| FCF Yield | -47.86% |
Analyst Forecast
The average price target for Pulmonx is $7.66, which is 367.07% higher than the current price. The consensus rating is "Buy".
| Price Target | $7.66 |
| Price Target Difference | 367.07% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 31.35% |
| EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Pulmonx has an Altman Z-Score of -2.67 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.67 |
| Piotroski F-Score | 3 |